Advances and Novel Treatment Options in Metastatic Melanoma
Advances and Novel Treatment Options in Metastatic Melanoma
English[eng]
9783040000000
melanoma||invasion||WNT5A||MARCKS||phosphorylation||MANS peptide||nanoparticles||cell therapy||tumor microenvironment||sex/gender||sex-hormones||immunity||microRNAs||immunotherapy||BRAF-mutant melanoma||BRAF inhibitor||mechanism of action||targeted therapy||tumour microenvironment||plasmacytoid dendritic cells||lactate dehydrogenase||TLR||interferon||CXCL10||TPC2||HIPPO||SOCE||metastasis||essential oils||angiogenesis||apoptosis||uveal melanoma (UM)||metastatic uveal melanoma (mUM)||prognostication||adjuvant therapy||metastatic therapy||metastatic dormancy||liver-directed-therapies||targeted-therapy||combined therapy||protein tyrosine phosphatase||PTPs inhibitors||melanoma immune infiltrate||BRAF inhibitors||microenvironment||resistance||therapy||therapeutic resistance||exosomes||extracellular vesicles||diagnosis||prognosis||ctDNA||liquid biopsy||prediction||patient stratification||BRAF||arthralgia||rheumatoid arthritis||carbonic anhydrase||hedgehog||cyclopamine||small molecules||acetazolamide||motility||metalloproteinases||FAK||cancer||mucosal melanoma||nivolumab||pembrolizumab||ipilimumab||radiotherapy||cholinergic system||acetylcholine||muscarinic receptors||nicotinic receptors||melanoma metastasis||ShcD adaptor protein||amoeboid motility||Rac1||DOCK4||melanoma PDX||target therapy||cancer stem cells||slow cycling phenotype||drug resistance||OXPHOS||lipid metabolism||cancer associated fibroblast||melanomagenesis||biomarkers||checkpoint inhibitor||PD-1||melanoma markers||cytokines||machine learning||Support Vector Machine||principal component analysis||BCL2L10||STAT3||cytotoxicity||survival||ABT-737||Bcl-2 family||ML258||HuR||MITF||metastases||siRNA||n/a
English[eng]
9783040000000
melanoma||invasion||WNT5A||MARCKS||phosphorylation||MANS peptide||nanoparticles||cell therapy||tumor microenvironment||sex/gender||sex-hormones||immunity||microRNAs||immunotherapy||BRAF-mutant melanoma||BRAF inhibitor||mechanism of action||targeted therapy||tumour microenvironment||plasmacytoid dendritic cells||lactate dehydrogenase||TLR||interferon||CXCL10||TPC2||HIPPO||SOCE||metastasis||essential oils||angiogenesis||apoptosis||uveal melanoma (UM)||metastatic uveal melanoma (mUM)||prognostication||adjuvant therapy||metastatic therapy||metastatic dormancy||liver-directed-therapies||targeted-therapy||combined therapy||protein tyrosine phosphatase||PTPs inhibitors||melanoma immune infiltrate||BRAF inhibitors||microenvironment||resistance||therapy||therapeutic resistance||exosomes||extracellular vesicles||diagnosis||prognosis||ctDNA||liquid biopsy||prediction||patient stratification||BRAF||arthralgia||rheumatoid arthritis||carbonic anhydrase||hedgehog||cyclopamine||small molecules||acetazolamide||motility||metalloproteinases||FAK||cancer||mucosal melanoma||nivolumab||pembrolizumab||ipilimumab||radiotherapy||cholinergic system||acetylcholine||muscarinic receptors||nicotinic receptors||melanoma metastasis||ShcD adaptor protein||amoeboid motility||Rac1||DOCK4||melanoma PDX||target therapy||cancer stem cells||slow cycling phenotype||drug resistance||OXPHOS||lipid metabolism||cancer associated fibroblast||melanomagenesis||biomarkers||checkpoint inhibitor||PD-1||melanoma markers||cytokines||machine learning||Support Vector Machine||principal component analysis||BCL2L10||STAT3||cytotoxicity||survival||ABT-737||Bcl-2 family||ML258||HuR||MITF||metastases||siRNA||n/a